Full-Life Technologies, a Shanghai, China-based radiotherapeutics company, raised USD $63.3M in funding.
The round, which included $47.3M in Series B equity financing and $16M in loan facilities, saw participation from Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital.
The financing will advance development of the company’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110M funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies.
Full-Life Technologies is a global radiotherapeutics company with operations in Belgium, Germany, and China, which seeks to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow.
Since completion of its Series A equity financing in 2022, Full-Life has achieved multiple significant milestones, including but not limited to:
- Advancing the company’s lead drug candidate, 225Ac-FL-020, towards Phase I clinical trials in metastatic castration-resistant prostate cancer (mCRPC) patients. Clinical trials are planned to start in both Europe and the U.S. in early 2024. Full-Life’s PSMA-targeting vector, FL-020, is specifically designed to deliver the highly potent alpha-emitter, Actinium-225.
- Assembling a pre-clinical portfolio including both first-in-class and best-in-class programs as well as development of the novel UniRDCTM discovery platform. UniRDCTM is a proprietary platform established to streamline the discovery process of RDC.
- Acquiring a 17,000 square meter of land in the Walloon region of Belgium, obtaining the required construction permit, and beginning construction of a 4,000 square meter state-of-the-art GMP-level radiopharmaceutical production facility. The facility is designed to advance Full-Life’s end-to-end solution and manufacture a broad spectrum of radiopharmaceuticals.
FinSMEs
04/01/2024